Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 12/20 | 0.57 |
| ▸ | APAF1 | O14727 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL369253 | 1.00 | SOAT1 (0.57) | SOAT1APAF1ALDH1A1LMNAMAPK1 | |
| SCHEMBL2485219 | 1.00 | SOAT1 (0.57) | SOAT1APAF1ALDH1A1LMNAMAPK1 | |
| SCHEMBL15732916 | 1.00 | SOAT1 (0.57) | SOAT1APAF1ALDH1A1LMNAMAPK1 | |
| SCHEMBL368936 | 1.00 | SOAT1 (0.57) | SOAT1APAF1ALDH1A1LMNAMAPK1 | |
| SCHEMBL15733152 | 0.99 | SOAT1 (0.56) | SOAT1APAF1ALDH1A1LMNAMAPK1 | |
| SCHEMBL15733049 | 0.94 | SOAT1 (0.56) | SOAT1APAF1ALDH1A1MAPK1HTT | |
| SCHEMBL15732826 | 0.89 | SOAT1 (0.51) | SOAT1APAF1ALDH1A1LMNAMAPK1 | |
| SCHEMBL2484804 | 0.83 | SOAT1 (0.50) | SOAT1APAF1ALDH1A1LMNAMAPK1 | |
| SCHEMBL20098762 | 0.79 | ALDH1A1 (0.49) | APAF1ALDH1A1ALOX5 | |
| SCHEMBL10895412 | 0.78 | ALDH1A1 (0.48) | APAF1ALDH1A1MAPK1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3182129-B1 | METHOD OF SCREENING A THERAPEUTIC AGENT FOR K-RAS MUTANT CANCER | RAND BIO SCIENCE INC (KR) | 2018-12-26 | — | — | EP | disclosed |
| EP-3182129-A1 | CHEMICAL INHIBITOR OF P53-SNAIL BINDING AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER DISEASE CONTAINING SAME AS ITS ACTIVE INGREDIENT | RAND Bio Science Inc. (KR) | 2017-06-21 | — | — | EP | disclosed |
| US-9400281-B2 | Method of screening of therapeutic agents for K-Ras mutant driven cancers | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2016-07-26 | — | — | US | disclosed |
| US-20140147866-A1 | COMPOUND FOR INHIBITING SNAIL-P53 BINDING AND THERAPEUTIC AGENT FOR CANCER INCLUDING THE COMPOUND AS EFFECTIVE COMPONENT | THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (KR) | 2014-05-29 | — | — | US | disclosed |
| US-20120015960-A1 | CHEMICAL INHIBITOR OF P53-SNAIL BINDING AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER DISEASE CONTAINING SAME AS ITS ACTIVE INGREDIENT | THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (KR) | 2012-01-19 | — | — | US | disclosed |
| EP-2377849-A2 | CHEMICAL INHIBITOR OF P53-SNAIL BINDING AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER DISEASE CONTAINING SAME AS ITS ACTIVE INGREDIENT | Pusan National University Industry-University Cooperation Foundation (KR) | 2011-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015960-A1 | CHEMICAL INHIBITOR OF P53-SNAIL BINDING AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER DISEASE CONTAINING SAME AS ITS ACTIVE INGREDIENT | TP53, TP53BP1, KRAS | SOAT1 2850/4885APAF1 1291/4885ALDH1A1 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.